GlassScriptPhysician profile
Krithika Mullengada
NPI 1992785562
$926.09
in general payments reported to CMS, 2019-2025
24 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.28 · 2020: $26.21 · 2021: $78.13 · 2022: $114 · 2023: $242 · 2024: $239 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $683.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $236.04 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Corcept Therapeutics | $117.37 | 2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.02 | 2019-2024 | Xifaxan |
| Novo Nordisk INC | $58.11 | 2019-2025 | Ozempic, Wegovy |
| Exact Sciences Corporation | $54.86 | 2024-2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $42.20 | 2022 | |
| Lilly USA, LLC | $28.89 | 2022-2025 | Mounjaro |
| Dexcom, INC. | $28.12 | 2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $24.68 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.84 | 2022 | |
| Nevro Corp. | $20.80 | 2024 | Senza |
| Bausch Health US, LLC | $19.21 | 2025 | Wellbutrin |
| Sumitomo Pharma America, INC. | $18.45 | 2025 | Gemtesa |
| Lundbeck LLC | $18.40 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $17.78 | 2025 | Recorlev |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $16.75 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $16.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.22 | 2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $15.28 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $15.00 | 2023 | Breztri |
| Esperion Therapeutics, INC. | $13.62 | 2025 | Nexletol |
| Biogen, INC. | $13.12 | 2021 | |
| Allergan, INC. | $12.67 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krithika Mullengada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.